Comparison of once-daily versus twice-daily combination of Ropinirole prolonged release in Parkinson's disease

BMC Neurology

Volumn 13, Issue , 2013, Pages

  Yun, Ji Young ^a   Kim, Han Joon ^b,c   Lee, Jee Young ^b   Kim, Young Eun ^d   Kim, Ji Seon ^e   Kim, Jong Min ^d   Jeon, Beom S ^b,c  

^a Mokdong Hospital   (South Korea)

^b Seoul National University   (South Korea)

^c Seoul National University Hospital   (South Korea)

^d Seoul National University Bundang Hospital   (South Korea)

^e Chungbuk National University Hospital   (South Korea)

Author keywords

Dopamine agonist; Motor control; Movement disorders; Parkinson's disease

Indexed keywords

PRAMIPEXOLE; ROPINIROLE;

ADULT; AGITATION; ARTICLE; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG RELEASE; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR CONTROL; MOTOR DYSFUNCTION; NAUSEA; OUTCOME ASSESSMENT; PARASOMNIA; PARKINSON DISEASE; PATIENT COMPLIANCE; QUESTIONNAIRE; RATING SCALE; SIDE EFFECT; SLEEP QUALITY; VIVID DREAM; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; BENZOTHIAZOLES; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PARKINSON DISEASE; QUESTIONNAIRES; RETROSPECTIVE STUDIES;

EID: 84883197459     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-13-113     Document Type: Article

References (7)

1. Obeso JA, Rodriguez-Oroz MC, Chana P, Lera G, Rodriguez M, Olanow CW. The evolution and origin of motor complications in Parkinson's disease. Neurology 2000, 55(11 Suppl 4):S13-S20. discussion S21-13.
2. Stocchi F, Hersh BP, Scott BL, Nausieda PA, Giorgi L, Ease PDMSI. Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study. Curr Med Res Opin 2008, 24(10):2883-2895. 10.1185/03007990802387130, 18768106.
3. Stocchi F, Giorgi L, Hunter B, Schapira AH. PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson's disease. Mov Disord 2011, 26(7):1259-1265. 10.1002/mds.23498, 21469195.
4. Grosset D, Antonini A, Canesi M, Pezzoli G, Lees A, Shaw K, Cubo E, Martinez-Martin P, Rascol O, Negre-Pages L, et al. Adherence to antiparkinson medication in a multicenter European study. Mov Disord 2009, 24(6):826-832. 10.1002/mds.22112, 19191340.
5. Tompson DJ, Vearer D. Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole: results of two randomized studies in patients with Parkinson's disease. Clin Ther 2007, 29(12):2654-2666. 10.1016/j.clinthera.2007.12.010, 18201581.
6. Jost WH, Buhmann C, Fuchs G, Greulich W, Hummel S, Korchounov A, Mungersdorf M, Schwarz M, Spiegel-Meixensberger M. Initial experience with ropinirole PR (prolonged release). J Neurol 2008, 255(Suppl 5):60-63.
7. Onofrj M, Bonanni L, De Angelis MV, Anzellotti F, Ciccocioppo F, Thomas A. Long half-life and prolonged-release dopamine receptor agonists: a review of ropinirole prolonged-release studies. Parkinsonism Relat Disord 2009, 15(Suppl 4):S85-S92.